Toll-like receptors targeting technology for the treatment of lymphoma

Maria Batool, Muhammad Ayaz Anwar, Sangdun Choi

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Introduction: The crucial role of Toll-like Receptors (TLRs) in innate and adaptive immune systems is well discussed in the literature. In cancer, TLRs act as a double-edged sword that can promote or suppress tumor growth. Areas covered: In this article, the authors uncover the potential role of TLRs in lymphomas, which are cancers related to the lymphatic system and blood cells. TLRs are de facto inflammation-inducing receptors that can either worsen disease or ameliorate lymphoma treatment. From this perspective, the usage of TLRs to modulate the immune system toward lymphoma regression is desirable. Various strategies have been used so far, and novel ways are being sought out to cure lymphoma. Expert opinion: TLR ligands have successfully been used to improve patient health; however, these receptors must be finely tuned to further optimize therapy. For a better outcome, novel specific ligands, improved pharmacodynamics, and unique targets should be discerned. Ligands with conjugated molecules, nanoparticles, and targeted drug delivery can highly optimize the therapy for lymphoma with various etiologies.

Original languageEnglish
Pages (from-to)1047-1059
Number of pages13
JournalExpert Opinion on Drug Discovery
Volume11
Issue number11
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Funding

This work was supported by the Mid-Career Researcher Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science, and Technology (NRF-2015R1A2A2A09001059), and by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI14C1992). This work was also partially supported by a grant from the Priority Research Centers Program through the National Research Foundation of Korea (NRF 2012-0006687).

FundersFunder number
Korea Health Industry Development Institute2012-0006687, HI14C1992
National Research Foundation of Korea
Ministry of Education, Science and TechnologyNRF-2015R1A2A2A09001059

    Keywords

    • B-cell receptor
    • Toll-like receptor
    • cancer therapy
    • ligand
    • lymphoma

    Fingerprint

    Dive into the research topics of 'Toll-like receptors targeting technology for the treatment of lymphoma'. Together they form a unique fingerprint.

    Cite this